Claims

1. Use of EC145 in the manufacture of a medicament for the treatment of a cancer in a patient, wherein

the medicament is to be administered with one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition; and wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

2. The use of claim 1 wherein the additional chemotherapeutic agent is a taxane.

3. The use of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

4. The use of claim 3 wherein the additional chemotherapeutic agent is docetaxel.

5. The use of claim 3 wherein the additional chemotherapeutic agent is paclitaxel.

6. The use of claim 1 wherein the cancer is an epithelial cancer.

7. The use of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The use of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The use of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The use of claim 1 wherein the additional chemotherapeutic agent is to be administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The use of claim 1 wherein the EC145 and the chemotherapeutic agent are to be administered in therapeutically effective amounts.

12. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The use of claim 11 wherein the effective amounts range from about 10 μg/kg to about 100 μg/kg of patient body weight.

15. The use of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The use of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

18. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are to be administered at doses lower than their maximum tolerable doses.

20. A kit comprising EC145 and one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is a taxane.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is docetaxel.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is paclitaxel.

25. The kit of claim 20 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of claim 20 wherein the EC145 is in the form of a reconstitutable lyophilizate.

30. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

31. Use of a dose of EC145 in the manufacture of a medicament for treatment of non-small cell lung cancer, wherein

the medicament is to be administered to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and


wherein the medicament is to be administered with a dose of docetaxel over one hour on day one of the three week cycle of therapy.

32. The use of claim 31 wherein the dose of EC145 is 2.5 mg.

33. The use of claim 31 wherein the dose of docetaxel is 75 mg/m^2 of body surface area.

Claims

1. Use of a compound of the formula



or a pharmaceutically acceptable salt thereof

in the manufacture of a medicament for the treatment of a non-small cell lung cancer in a patient, wherein the medicament is to be administered with a taxane.


2. The use of claim 1 wherein the taxane is selected from the group consisting of docetaxel and paclitaxel.

3. The use of claim 2 wherein the taxane is docetaxel.

4. The use of claim 2 wherein the taxane is paclitaxel.

5. The use of claim 1 wherein the taxane is to be administered at a dose that is 50 to 80% of the maximum tolerated dose for the taxane.

6. The use of claim 1 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane are to be administered in therapeutically effective amounts.

7. The use of claim 6 wherein the therapeutically effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

8. The use of claim 6 wherein the therapeutically effective amounts range from about 1 μg/m^2 to about 300 mg/m^2 of body surface area.


9. The use of claim 6 wherein the therapeutically effective amounts range from about 10 μg/kg to about 100 μg/kg of patient body weight.

10. The use of claim 1 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane have a purity of at least 90% based on weight percentage.

11. The use of claim 1 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof is in the form of a reconstitutable lyophilizate.

12. The use of claim 1 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane are in sterile, pyrogen-free aqueous solutions.

13. The use of claim 1 wherein the compound of the formula



or a pharmaceutically acceptable salt thereof and the taxane are to be administered at doses lower than their maximum tolerable doses.

14. A kit comprising a compound of the formula




or a pharmaceutically acceptable salt thereof and a taxane.

15. The kit of claim 14 wherein the taxane is selected from the group consisting of docetaxel and paclitaxel.

16. The kit of claim 15 wherein the taxane is docetaxel.


17. The kit of claim 15 wherein the taxane is paclitaxel.

18. The kit of claim 14 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane are in therapeutically effective amounts.

19. The kit of claim 14 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane are in sterile containers or packages.

20. The kit of claim 14 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane have a purity of at least 90% based on weight percentage.

21. The kit of claim 14 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof and the taxane have a purity of at least 95% based on weight percentage.

22. The kit of claim 14 wherein the compound of the formula




or a pharmaceutically acceptable salt thereof is in the form of a reconstitutable lyophilizate.

23. The kit of claim 14 wherein the compound of the formula



or a pharmaceutically acceptable salt thereof and the taxane are in sterile, pyrogen-free aqueous solutions.


24. Use of a dose of a compound of the formula



or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of non-small cell lung cancer, wherein the medicament is to be administered to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and

wherein the medicament is to be administered with a dose of docetaxel over one hour on day one of the three week cycle of therapy.


25. The use of claim 24 wherein the dose of the compound of the formula



or a pharmaceutically acceptable salt thereof is 2.5 mg.

26. The use of claim 24 wherein the dose of docetaxel is 75 mg/m^2 of body surface area.

27. The use of claim 1 wherein the compound of the formula



or a pharmaceutically acceptable salt thereof and the taxane are in sterile containers or packages.